Related Experiment Video

Updated: Oct 3, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.7K

Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects

Shengjie Tang1, Chao Qin1,2, Haiyang Hu1,2

  • 1Department of Thoracic Surgery, Suining Central Hospital, An Affiliated Hospital of Chongqing Medical University, Suining 629099, China.

Cells
|February 15, 2022
PubMed

Insights

Immune checkpoint inhibitors (ICIs) show improved safety and effectiveness for non-small cell lung cancer (NSCLC) treatment compared to traditional therapies. This review covers clinical trials, efficacy data, and biomarkers for advanced NSCLC patients.

Area of Science:

  • Oncology
  • Immunotherapy

Background:

  • Non-small cell lung cancer (NSCLC) is a leading cause of cancer deaths globally.
  • Current NSCLC treatments like surgery, chemotherapy, and radiotherapy have limited effectiveness.
  • Emerging immunotherapies offer new hope for advanced NSCLC patients.

Purpose of the Study:

  • To review clinical trials of immune checkpoint inhibitors (ICIs) in NSCLC treatment.
  • To summarize available data on the clinical efficacy of ICI immunotherapies.
  • To discuss emerging biomarkers for guiding NSCLC treatment with ICIs.

Main Methods:

  • Literature review of clinical trials and experimental studies on ICIs for NSCLC.
  • Analysis of clinical efficacy data from published studies.
  • Examination of research on biomarkers associated with ICI response.

Main Results:

  • ICIs demonstrate superior safety and efficacy compared to traditional NSCLC treatments.
  • Clinical trials show promising outcomes for advanced NSCLC patients treated with ICIs.
  • Biomarker research is crucial for personalizing NSCLC immunotherapy.

Conclusions:

  • Immune checkpoint inhibitors represent a significant advancement in NSCLC treatment.
  • Further research into biomarkers will optimize the use of ICIs in clinical practice.
  • ICIs offer improved therapeutic options for patients with advanced NSCLC.
Keywords:
CTLA-4PD-1/PD-L1biomarkersimmune checkpoint inhibitorsimmunotherapynon-small cell lung cancer

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

597
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
711